COMPANY PROFILE

OverT Bio

Explore full profile

Discovering novel genes to drive revolutionary cell-based treatments

New York City, United StatesFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About OverT Bio

OverT Bio operates at the cutting edge of cell and gene therapy, focusing on the development of next-generation cellular therapies for solid tumors. The company leverages innovative platforms such as OverTarget, which utilizes pooled functional screening and synthetic genomics to engineer immune cells. OverT Bio's team comprises computational and experimental biologists, immunologists, and genome engineers, all working together to create effective and safe treatments. The company is backed by top-tier TechBio investors and has published its scientific advancements in prestigious journals like Nature and The New England Journal of Medicine. OverT Bio serves the biotechnology and healthcare markets, targeting medical institutions and research organizations. Its business model revolves around the discovery and development of proprietary therapeutic solutions, generating revenue through partnerships, licensing agreements, and potentially direct sales of its therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: New York City, United States
Employees: 13
Open positions: 1
Dealroom signal: 72.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Nov 2024	$120K	—	ScaleReady	↗
SEED✓Equity / VC	May 2024	$16M	$64M	Alexandria Venture Investments · Civilization Ventures · Wing Venture Capital · Gaingels	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

OverT Bio website traffic

Latest recorded traffic for OverT Bio is 2K monthly website visits, down 37.5% over the last three months. OverT Bio's team grew 0% over the past year.

Latest monthly visits2K 3-month web change-37.5% 1-year team growth0%

Monthly website visitsJan 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OLOlgramInnovations from the sea to tackle antibiotic resistance \| Olgram	Paris, France	Operational	6	$4.5M	$6.6M
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
HBHaploX BiotechnologyShenzhen-based genetic sequencing company	Shenzhen, China	Operational
VTVerve TherapeuticsFocused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary	Cambridge, United States	Acquired
PMPraxis Precision MedicinesDeveloping therapies for central nervous system disorders based on genetic insights into neuronal imbalance	Cambridge, United States	Operational
NANapigenA biotech company that addresses novel genome engineering of various organisms such as plants, microbes and animals	Wilmington, United States	Operational
OBOctant BioDeveloping synthetic technology and applying next-generation DNA sequencing, gene synthesis, and gene editing to discover safer, more effective, cheaper drugs	Emeryville, United States	Operational
OTOMass TherapeuticsA drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets	Oxford, United Kingdom	Operational